CPC
GBT

Consolidated Planning Corp’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Consolidated Planning Corp’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-250
Closed -$6K – 499
2021
Q3 		$6K Buy
+250
New +$7.35K ﹤0.01% 353

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Consolidated Planning Corp's GBT Position: Q4 2021 in Review

Consolidated Planning Corp sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2021, closing a stake of 250 shares — an estimated $6K sold.

Consolidated Planning Corp first reported a position in GBT in Q3 2021 and held it in 1 quarter. The position peaked at $6K in Q3 2021. 206 funds tracked by Wall St. Rank hold GBT as of Q4 2021.

  • Consolidated Planning Corp reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
  • Consolidated Planning Corp sold 250 Global Blood Therapeutics, Inc. shares in Q4 2021, an estimated $6K.
  • Consolidated Planning Corp first reported a position in Global Blood Therapeutics, Inc. in Q3 2021 and held it in 1 quarter.
  • Consolidated Planning Corp's Global Blood Therapeutics, Inc. position peaked at $6K in Q3 2021.
  • 206 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2021.

Based on Consolidated Planning Corp's 13F filing for Q4 2021, filed 11 Feb 2022.